2024 Revenues ($USD) : $44.47B

France-based Sanofi S.A. (Nasdaq: SNY) demonstrated solid commercial execution in 2024, delivering full-year net sales of €41.1 billion, equivalent to $44.47 billion based on average 2024 exchange rates. This represented an 11.3% increase at constant exchange rates (CER), although reported USD sales saw a slight decline from $46.59 billion in 2023 due to currency fluctuations. Growth momentum was sustained through the fourth quarter, which saw sales climb 10.3% (CER) to €10.6 billion. Headquartered in Paris, Sanofi employed approximately 82,878 people globally and held total assets of $143.72 billion at year-end.

Sanofi invested $8.00 billion in R&D during 2024, representing 18.0% of its net sales, an increase in R&D intensity compared to the 15.6% ratio in 2023. A standout performer was the company's vaccine division, which posted 13.5% growth (CER), exceeding €8 billion in annual sales. Beyfortus, its RSV preventative antibody co-developed with AstraZeneca, was a key driver, rapidly achieving blockbuster status with reported sales of €1.7 billion (approx. $1.8 billion) during its first full launch cycle.

CEO Paul Hudson framed these results within the company's ongoing strategic shift, noting, "We achieved double-digit sales growth in 2024 while pursuing the transformation of the company."

Recent regulatory and clinical milestones underscore Sanofi's focus across multiple therapeutic fronts. Key developments include:

Rare diseases and hematology: In February 2025, Sarclisa gained approval in Japan for newly diagnosed multiple myeloma, expanding its reach. Furthermore, the investigational BTK inhibitor, rilzabrutinib, received US orphan drug designations for warm autoimmune hemolytic anemia (wAIHA) and IgG4-related disease (IgG4-RD) in April 2025 and remains under FDA review for immune thrombocytopenia (ITP), highlighting its potential across several immune-mediated hematologic conditions.

Immunology and inflammation: Dupixent continues its expansion, gaining approval in Japan for chronic obstructive pulmonary disease (COPD) – a first for a biologic in this indication there – in March 2025. Sanofi also received FDA Fast Track designation for its chlamydia vaccine candidate and secured Priority Review for its multiple sclerosis candidate, tolebrutinib, signaling regulatory confidence in these programs.

Strategic bolt-on: Aligning with its focus on immunology, Sanofi announced plans in March 2025 to acquire a bispecific myeloid cell engager asset from Dren Bio, aimed at enhancing B-cell depletion capabilities and further strengthening its pipeline in inflammatory and immune-mediated diseases.